Our portfolio company Anthos Theraputics announced groundbreaking trial data for their anti #bloodclot 🩸 treatment, abelacimab, at the American_Heart Conference — a 67% reduction in bleeding compared to a current standard of care. Hear more from StopTheClot and #Blackstone leaders. 👆🔊 The treatment also reduced the risk of potentially life-threatening major bleeding events by 74% and gastrointestinal bleeding by 93%. That makes abelacimab a potential game-changer for patients at risk of #strokes and #heartattacks. We’re thrilled to back Anthos and this promising new treatment. Learn more about our long-term partnership with Anthos and why we’re so excited about this latest milestone at the link in our bio. 🔗